Mitokinin, Inc.

It has been a challenging month for Bethesda, Maryland-based Gain Therapeutics, Inc. Shares of the company have fallen dramatically since 14 June, when it priced a public offering to raise $11m. The

Merger and acquisition activity in Q4 2023 flipped the script after a sluggish third quarter, with 10 transactions valued at $1bn or more and two valued above $10bn, according to data recorded by Eval

AbbVie Inc. 's recent regulatory setback for a promising Parkinson's disease product has not skewed the US major's interest in the neurodegenerative disease, as the acquisition of Mitokinin, Inc. cl

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Biolojic To Use Computational Platform